Inventor
GRECO MICHAEL NICHOLAS
US11 patents
Patents
11 patentsUS10239864B2Mar 26, 2019
2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof
BETA PHARMA INC5 citations81
US9878994B2Jan 30, 2018
2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof
BETA PHARMA INC8 citations81
US10590111B2Mar 17, 2020
Substituted 2-anilinopyrimidine derivatives as EGFR modulators
BETA PHARMA INC2 citations70
US12187707B2Jan 7, 2025
Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof
BETA PHARMA INC0 citations59
US11414401B2Aug 16, 2022
Substituted 2-anilinopyrimidine derivatives as EGFR modulators
BETA PHARMA INC0 citations59
US11352341B2Jun 7, 2022
2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof
BETA PHARMA INC0 citations59
US11180478B2Nov 23, 2021
Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
BETA PHARMA INC0 citations59
US11052086B2Jul 6, 2021
2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
BETA PHARMA INC0 citations59
US12595246B2Apr 7, 2026
Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
BETA PHARMA INC0 citations49
US12390464B2Aug 19, 2025
Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors
BETA PHARMA INC0 citations49
US12258365B2Mar 25, 2025
Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof
BETA PHARMA INC0 citations49